What is Trevi Therapeutics Inc's share price today?
Trevi Therapeutics Inc (TRVI) share price today is $13.99 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $14.39 and a day low of $13.52.What exchange does Trevi Therapeutics Inc stock trade on, and under what ticker symbol?
Trevi Therapeutics Inc stock trades on NASDAQ under the ticker symbol TRVI.What is Trevi Therapeutics Inc's market capitalization?
Trevi Therapeutics Inc's market capitalization is $1.94B as of November 5, 2026 at 2:29 AM IST.What is Trevi Therapeutics Inc's price-to-earnings (P/E) ratio?
Trevi Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.What is Trevi Therapeutics Inc's price-to-book (P/B) ratio?
Trevi Therapeutics Inc's price-to-book (P/B) ratio is 6.00 as of November 4, 2026.Can Indian investors buy Trevi Therapeutics Inc shares?
Yes, You can buy Trevi Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Trevi Therapeutics Inc shares from India?
Indian investors can buy Trevi Therapeutics Inc shares in three steps: 1. Search Trevi Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Trevi Therapeutics Inc shares for Indian investors?
Since Trevi Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Trevi Therapeutics Inc shares via Tickertape?
Indian investors can start investing in Trevi Therapeutics Inc (TRVI) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.7146 shares at the current price of $13.99.
$
₹
$13.990.95% (+0.13)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
6.00
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-0.35
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 11 analysts reports
Buy11 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+101.51%
Earnings Growth
-49.69%
Rev. Growth
—
Company Profile
Company Profile
P/E Ratio
46.00
46.00
1Y Return
56.59%
56.59%
Buy Reco %
83.87
83.87
P/E Ratio
41.05
41.05
1Y Return
48.81%
48.81%
Buy Reco %
69.56
69.56
P/E Ratio
149.85
149.85
1Y Return
79.29%
79.29%
Buy Reco %
67.85
67.85
P/E Ratio
30.82
30.82
1Y Return
31.97%
31.97%
Buy Reco %
41.66
41.66
P/E Ratio
26.39
26.39
1Y Return
11.26%
11.26%
Buy Reco %
75.00
75.00
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$13.98Baseline
Analyst Target - 1 year
Target$28.18+101.51%
All values in $
2026
Current$13.98Baseline
Analyst Target - 1 year
Target$28.18+101.51%
All values in $
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-0.32Baseline
Forecast for Dec 2026
High$-0.34-6.25%
Average$-0.48-49.69%
Low$-0.58-81.25%
All values in $
2025
Current$-0.32Baseline
Forecast for Dec 2026
High$-0.34-6.25%
Average$-0.48-49.69%
Low$-0.58-81.25%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0.14 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | - | -0.03 | -0.03 | - |
| Net Income | -10.90 | -12.35 | -13.24 | -11.41 | -10.34 | -12.30 | -11.80 | -8.31 | -13.19 | -17.79 |
| Net Profit Margin | - | - | - | -7818.49% | - | - | - | - | - | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Trevi Therapeutics Inc | - | 6.00 | - |
| Eli Lilly and Company | 46.00 | 31.35 | 1.35 |
| Johnson & Johnson | 41.05 | 8.06 | 3.07 |
Price Comparison
Price Comparison
Compare TRVI with any stock or ETFCompare TRVI with any stock or ETF
Comparing from
TRVI
LLY
JNJ
The 12-month consensus target implies 101.51% growth, versus a trailing 3-year CAGR of 113.35%.